Gilead Sciences ($GILD) has been busy in India and Japan signing licensing agreements for at least four of its drugs, three for hepatitis C, the other for HIV treatments.
In India, Natco Pharma signed an agreement for local nonexclusive rights to produce and market at any price it chooses generic versions of Sovaldi, Harvoni and an NS5A inhibitor. The first two are for treating chronic hepatitis C, the third a single-dose combination with sofosbuvir, the API of Sovaldi, intended to treat all 6 hep C genotypes.
In the Japan deal, which involves a chain of licenses, Japan Tobacco has outlicensed two new tenofovir-based HIV drugs to fellow Japan-based drug maker Torii Pharmaceutical to market at home with exclusive rights. JT, in turn, has exclusive Japan development rights from the owner of the drugs, Gilead.
Tenofovir is at least one active pharmaceutical ingredient in three of Gilead's drugs with U.S. FDA clearance: Viread, Truvada and Stribild.